Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Purpose: Drugs that blockade interaction between programmed cell-death protein 1 (PD-1) and its ligand (PD-L1) are promising. Immune-related adverse events (irAEs) might be associated with favorable clinical outcomes, and thyroid dysfunction is one of the most common irAE. We evaluated the associati...

Full description

Bibliographic Details
Main Authors: Hye In Kim, Mijin Kim, Se-Hoon Lee, So Young Park, Young Nam Kim, Hosu Kim, Min Ji Jeon, Tae Yong Kim, Sun Wook Kim, Won Bae Kim, Sang-We Kim, Dae Ho Lee, Keunchil Park, Myung-Ju Ahn, Jae Hoon Chung, Young Kee Shong, Won Gu Kim, Tae Hyuk Kim
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:OncoImmunology
Subjects:
biomarkers
immunotherapy
non-small cell lung cancer
programmed cell death 1
thyroid
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1375642

Internet

http://dx.doi.org/10.1080/2162402X.2017.1375642

Similar Items